#SLDB

StockTitan

@stocktitan.net

4 days ago

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial Solid Biosciences (NASDAQ: SLDB) reported interim positive Phase 1/2 INSPIRE DUCHENNE results for SGT-003 on March 11, 2026, with 40 participants dosed as of that date. Data show robust microdystrophin expression, restoration of DAPC components (beta-sarcoglycan, nNOS), biomarker improvements, and stabilization-to-improvement in LVEF; safety remained generally favorable. The company plans additional FDA meetings in H1 2026 to discuss a potential accelerated approval pathway and will provide a mid-2026 update.

#SLDB Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 week ago

Solid Biosciences Announces Oversubscribed $240 Million Private Placement Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of

#SLDB Solid Biosciences Announces Oversubscribed $240 Million Private Placement

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

2 months ago

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 Solid Biosciences (NASDAQ: SLDB) provided a 2026 outlook highlighting clinical progress across neuromuscular and cardiac programs and expanded access to its next‑generation capsid AAV‑SLB101.Key points: 33 participants dosed with SGT‑003 in the Phase 1/2 INSPIRE Duchenne trial 50+ agreements for AAV‑SLB101.

#SLDB Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

2 months ago

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia - SGT-212 has received FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations - - Dosing of the first participant in the Phase 1b FALCON trial has been completed, with initial data expected in H2 2026, subject to participant enrollment - CHARLESTOWN, Mass., Jan. 12, 2026 (GLOBE

#SLDB Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

2 months ago

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia Solid Biosciences (NASDAQ: SLDB) announced dosing of the first participant in FALCON, its Phase 1b first‑in‑human trial of SGT‑212 for Friedreich’s ataxia on January 12, 2026. SGT‑212 uses a dual‑route approach: MRI‑guided stereotactic intradentate nuclei (IDN) infusion to the cerebellar dentate nuclei followed by an intravenous infusion, aiming to restore frataxin. Intra‑procedural MRI confirmed IDN targeting and coverage above company thresholds. The company expects preliminary safety insights in coming months and an initial data update in H2 2026, subject to participant enrollment.

#SLDB Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

2 months ago

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today shared that the U.S. Department of Health and Human Services (HHS)

#SLDB Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

3 months ago

#SLDB Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

3 months ago

#SLDB Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

4 months ago

#SLDB Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

7 months ago

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Solid Biosciences (NASDAQ:SLDB) has received FDA Fast Track designation for SGT-501, its novel gene therapy treatment for catecholaminergic polymorphic ventricular tachycardia (CPVT). This designation adds to previously received FDA IND clearance, Orphan Drug, and Rare Pediatric Disease designations.SGT-501 is designed as a first-in-class AAV-based gene therapy that delivers a functional CASQ2 gene to cardiac muscle cells, targeting the underlying causes of CPVT, a life-threatening cardiac condition. The therapy has received both FDA IND clearance and Health Canada CTA approval.The company plans to initiate a Phase 1b clinical trial in Q4 2025, which will be a first-in-human, open-label, multicenter study evaluating the safety, tolerability, and efficacy of SGT-501.

#SLDB Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

www.stocktitan.net/news/SLDB/solid-bioscien...

Thiard News@F4F

@newsen.bsky.social

8 months ago

Kaskela Law LLC Investigates Solid Biosciences Inc. Amidst Shareholder Concerns Kaskela Law LLC initiates an investigation into Solid Biosciences Inc. due to significant stock price declines. Shareholders are urged to participate.

Kaskela Law LLC Investigates Solid Biosciences Inc. Amidst Shareholder Concerns #USA #Philadelphia #Kaskela_Law #Solid_Biosciences #SLDB

StockTitan

@stocktitan.net

10 months ago

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates Solid Biosciences (NASDAQ: SLDB) reported Q1 2025 financial results and provided updates on its gene therapy pipeline. The company's cash position strengthened to $306.9 million, extending runway into H1 2027. Net loss widened to $39.3 million from $24.3 million year-over-year.Key pipeline updates include: 1) Ongoing participant dosing in the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, with positive initial data showing robust microdystrophin expression and improved biomarkers; 2) FDA-cleared IND for SGT-212 for Friedreich's Ataxia, with first participant dosing expected in H2 2025; 3) Planned IND submission for SGT-501 for CPVT in H1 2025.The company's proprietary capsid AAV-SLB101 has secured 19 partnership agreements, with more expected. R&D expenses increased to $30.9 million, primarily due to increased costs for SGT-003 development.

#SLDB Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 year ago

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Solid Biosciences (NASDAQ: SLDB) reported its Q4 and full-year 2024 financial results, highlighting positive initial data from the INSPIRE DUCHENNE trial for SGT-003, their next-generation Duchenne gene therapy. The company ended 2024 with $148.9 million in cash and secured an additional $200 million through a February 2025 offering, extending runway into H1 2027.Key developments include:FDA IND clearance for SGT-212 treating Friedreich's ataxia, with first participant dosing expected in H2 2025INSPIRE DUCHENNE trial showed promising results with mean microdystrophin expression of 110% and 78% dystrophin positive fibersPlanned FDA meeting in mid-2025 to discuss accelerated approval pathways for SGT-003Financial results show R&D expenses increased to $96.4 million for 2024 (vs $76.6M in 2023), while net loss widened to $124.7 million (vs $96.0M in 2023). The company maintains partnerships with 19 institutions for its AAV-SLB101 capsid technology.

#SLDB Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/SLDB/solid-bioscien...

INSIDEALERT

@insidealert.bsky.social

1 year ago

#SLDB #JBHT #RZLT

Some of the largest recent insider purchases we've seen:

#finsky #econsky #stockmarket #insidertrading

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #SLDB ) Solid Biosciences Inc. (NASDAQ: SLDB) Rises Sharply in 2/18 Early Trading Session

Market Wire News

@marketwirenews.com

1 year ago

JUST IN: ( NASDAQ: #SLDB ) Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

StockTitan

@stocktitan.net

1 year ago

Massive $200M Capital Raise: Elite Healthcare Investors Back Solid Biosciences Growth Plan Solid Biosciences prices 35.7M share offering at $4.03, backed by top-tier investors like Bain Capital and RA Capital, raising $200M for expansion

#SLDB Solid Biosciences Announces Pricing of Underwritten Offering

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 year ago

Clinical Trial Breakthrough: Revolutionary Gene Therapy Achieves 110% Dystrophin in Duchenne Patients Initial data shows exceptional 110% dystrophin expression, significant biomarker improvements, and potential cardiac benefits in Duchenne trial, with FDA meeting planned

#SLDB Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 year ago

Solid Biosciences Secures FDA Fast Track Status for Novel Dual-Route Friedreich's Ataxia Gene Therapy Breakthrough SGT-212 therapy receives FDA Fast Track designation, accelerating development of first dual-route gene treatment for Friedreich's ataxia. Phase 1b trial set for late 2025.

#SLDB Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

www.stocktitan.net/news/SLDB/solid-bioscien...

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#NLY, #SLDB, #SPIR, #ADSE, #IR

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

1 year ago

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #NLY 4.8x
2. #IBRX 4.5x
3. #RF 3.0x
4. #SLDB 3.0x
5. #SPIR 2.9x

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

1 year ago

Solid Biosciences Added to Nasdaq Biotechnology Index in Latest Market Recognition Precision genetic medicine company Solid Biosciences joins the prestigious Nasdaq Biotechnology Index, marking significant milestone for its neuromuscular and cardiac programs.

#SLDB Solid Biosciences Added to the Nasdaq Biotechnology Index

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 year ago

#SLDB Solid Biosciences to Participate at Upcoming Investor Conferences

www.stocktitan.net/news/SLDB/solid-bioscien...

StockTitan

@stocktitan.net

1 year ago

#SLDB Solid Biosciences to Present at the Jefferies London Healthcare Conference

www.stocktitan.net/news/SLDB/solid-bioscien...

InsiderFinance

@insiderfinance.com

1 year ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IONQ, #RGR, #GT, #SLDB, #WBA

#OptionFlow #OptionsTrading #Trading

Market Wire News

@marketwirenews.com

1 year ago

Just In: ( NASDAQ: #SLDB ) Buy Recommendation Issued On SLDB By H.C. Wainwright

#StockMarket #News